Navigation Links
Dr. H. Daniel Perez Joins Celtaxsys Board of Directors
Date:6/6/2011

SAN FRANCISCO, June 6, 2011 /PRNewswire/ -- Celtaxsys, Inc., a private biopharmaceutical company defining new therapeutics in inflammation, announces the appointment of life sciences industry veteran, H. Daniel Perez, M.D., to its Board of Directors (BOD).

"We are delighted that Dr. Perez has joined the Celtaxsys team," says Dr. Michael R. Hanley, CEO and Chairman of the Board of Celtaxsys. "He brings more than 25 years of high level pharmaceutical executive experience to the BOD, in addition to scientific and commercial accomplishments related to Celtaxsys' mission.  We look forward to working closely with Dr. Perez."  

"I am excited about the opportunities that an innate immunity company brings to the therapeutic field," commented Dr. Perez. "This is an area that is close to my heart and has not received the attention that it deserves.  I believe Celtaxsys will bring new paradigms to the forefront of innovative therapeutics."

H. Daniel Perez, M.D., is a Venture Partner with Bay City Capital, and was previously President and CEO of Berlex Biosciences until its acquisition by Bayer in 2006. He is on the Board of Directors of Cleveland Biolabs (a public company, CBLI), Presidio Pharmaceuticals, and F&P Pharmaceuticals (privately held companies), the Scientific Advisory Boards of Cardium (a public company, CDTP, CXM), Vertex Pharmaceuticals neurodegenerative diseases (VRTX, Nasdaq), Glaxo GSK, (Neuroinflammation, China) and the Advisory Board for the Gladstone Institutes at the University of California, San Francisco (UCSF). Dr. Perez received his medical degree in Buenos Aires, Argentina and completed his medical training at Beth Israel-Mount Sinai and New York University, in New York City. Dr. Perez has published extensively and is the author of a number of patents.

About Celtaxsys

Celtaxsys is a privately-held early discovery company with operations in San Francisco, CA and Atlanta, GA. The Company is focused on the discovery and development of therapeutics to treat inflammation by control of innate immunity. Celtaxsys has pioneered an innovative technology platform to identify novel immunoregulators based on migration and activation of cells from the innate immune system. Lead candidates are undergoing preclinical optimization.


'/>"/>
SOURCE Celtaxsys, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Wyeth Names Daniel J. McIntyre Vice President, Corporate Communications
2. Datafarm, Inc., Announces the Appointment of Daniel F. Orfe to Vice President, Global Regulatory Submission Services
3. Dr. Daniel Ronel Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler
4. Laureate Pharma Appoints Daniel E. Leone as Vice President of Business Development
5. BMP Sunstone Appoints Daniel Harrington to Board of Directors
6. Daniel Dunn Joins Brooks Instrument as Director of Customer Service
7. Rensselaer professor Daniel Lewis receives NSF CAREER Award
8. John Grisham Joins Focused Ultrasound Surgery Foundation Board, Citing Novel Technologys Potential to Help Millions of Patients
9. Nicholas J. Hart Joins Emisphere as Vice President, Strategy and Development
10. GM Exec Joins Bio-Reaction Industries Board of Directors
11. The National Cancer Institute Joins the Global Community of Scientists Now Using BIOMARKERcenter From Thomson Reuters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... They ... a complex biological network, a depiction of a system of linkages and connections ... Korkin, PhD, associate professor of computer science at Worcester Polytechnic Institute (WPI) and ...
(Date:10/12/2017)... ... 12, 2017 , ... AMRI, a global contract research, development ... patient outcomes and quality of life, will now be offering its impurity solutions ... new regulatory requirements for all new drug products, including the finalization of ICH ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its ... 2018 in San Francisco, CA. The Summit brings together current and former FDA office ... directors and government officials from around the world to address key issues in device ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... and pregnancy rates in frozen and fresh in vitro fertilization (IVF) ... maternal age to IVF success. , After comparing the results from the fresh ...
Breaking Biology Technology:
(Date:8/23/2017)... , Aug. 23, 2017  The general public,s help is being enlisted ... bacteria that live in and on the human body –and are believed ... The Microbiome Immunity ... human microbiome, starting with the gut. The project's goal is to help ... credit: IBM ...
(Date:6/14/2017)... (NYSE: IBM ) is introducing several innovative partner startups ... collaboration between startups and global businesses, taking place in ... nine startups will showcase the solutions they have built with ... France is one of the ... percent increase in the number of startups created between 2012 ...
(Date:4/24/2017)... WASHINGTON , April 24, 2017 ... counsel and partner with  Identity Strategy Partners, LLP ... "With or without President Trump,s March 6, ... Foreign Terrorist Entry , refugee vetting can be instilled ... refugee resettlement. (Right now, all refugee applications are ...
Breaking Biology News(10 mins):